|
AbSorber hosting an Early Morning Symposium during the upcoming TTS Congress in Vancouver, August 16
Improving outcomes in kidney transplantation: Non-HLA antibodies and Enhanced Clinical Risk Assessment
HLA-specific antibodies present before kidney transplantation or induced after transplantation have been associated with hyperacute and acute vascular rejection episodes, graft loss, and poor long-term graft survival. There is increasing evidence that the presence of non-HLA antibodies reactive with donor endothelial cells contribute to short and long term complications in renal transplant recipients. During the symposium enhanced risk assessment focusing on the detection of non-HLA antibodies will be discussed.
Program
AbSorber is excited about the very positive interest that XM-ONE® has received in the transplant community around the world. AbSorber's symposium, at this important congress, will give the participants an even better understanding of the clinical role of XM-ONE® in organ transplantation, according to Anders Karlsson, CEO of AbSorber. With this newsletter AbSorber would like to encourage those of you joining the TTS Congress in Vancouver to also come and join this early morning session.
XM-ONE® is a standardized, cell based, crossmatch test for clinical use. The use of XM-ONE® allows you to identify patients at risk for developing acute rejections and post-transplant complications. XM-ONE® provides additional information compared to the currently used lymphocyte crossmatch tests and therefore improves the basis for risk assessment prior to transplantation. For further information see package insert or visit www.absorber.se.
Forward this email to a friend or colleague by clicking here.
|
